StockpollyBeta
Get App
Delisting riskPopularity #5,362
RVPH · NASDAQ · Biotechnology

Reviva Pharmaceuticals (RVPH)

Develops brilaroxazine-led therapies for CNS, inflammatory, and cardiometabolic diseases.

$0.5040
vs last close−0.02 (−4.55%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
11108886764432,617,543
Research & development986675442211,394,569
222322222221,222,974
General & administrative222322222221,222,974
Other expenses000000000000
Operating income−11−10−8−8−8−6−7−6−4−4−3−2,617,543
00000000000172,344
Interest income00000000000176,319
Interest expense00000000000−2,935
Other non-operating income000000000000
Income before tax−10−10−7−8−8−6−6−6−4−3−3−2,445,199
Income tax expense000000000002,632
Net income from continuing operations−10−10−7−8−8−6−6−6−4−3−3−2,447,831
Net income−10−10−7−8−8−6−6−6−4−3−3−2,447,831
EPS, basic−$8.73−$7.20−$5.00−$5.20−$5.00−$3.20−$2.60−$2.40−$1.10−$5.21−$0.46−$0.19
EPS, diluted−$8.73−$7.20−$5.00−$5.20−$5.00−$3.20−$2.60−$2.40−$1.10−$5.21−$0.46−$0.19
Weighted average shares, basic1112222244713
Weighted average shares, diluted1112222244713
EBITDA−11−10−7−8−8−6−6−6−4−3−3−2,617,543
Depreciation & amortization0100080000000
EBIT−11−10−7−8−8−6−6−6−4−3−30